Cite
HARVARD Citation
de Rauglaudre, B. et al. (2022). Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. Therapeutic advances in medical oncology. p. . [Online].